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Background: Ovarian stimulation (OS) for poor ovarian response (POR) patients is
still a major challenge in assisted reproductive techniques. Aromatase inhibitors as
co-treatment in antagonist protocol are suggested to these patients, but there are
controversial reports.
Objective: To evaluate the effectiveness Letrozole (LZ) as adjuvant treatment
in gonadotropin-releasing hormone (GnRH)-antagonist protocol in POR patients
undergoing in vitro fertilization/intracytoplasmic sperm injection cycles.
Materials and Methods: This double-blind randomized clinical trial was conducted
in Arash women’s hospital. One hundred sixty infertile women with POR based on
Bologna criteria were allocated into two groups randomly: LZ + GnRH-antagonist (LA)
and placebo + GnRH-antagonist (PA) groups. In the experimental group, the patients
received 5 mg LZ on the first five days of OS with 150 IU of recombinant human
follicle-stimulating hormone (rFSH) and 150 IU of human menopausal gonadotropin
(HMG). The cycle outcomes were compared between groups.
Results: The total number of retrieved oocytes and the metaphase II oocytes in
LA-treated group were significantly higher than those in the control group (p = 0.008, p =
0.002). The dosage of hMG used and the duration of OS and antagonist administration
in LZ-treated group were significantly lower than those of the control group. The
number of patients with no oocyte, in the control group, was higher than the LZ-treated
group, and the clinical pregnancy rate in LA-treated group (25%) was higher than the
control group (18%); however, the differences were not significant statistically.
Conclusion: Adding 5 mg of LZ to rFSH/hMG antagonist protocol may improve the in
vitro fertilization/intracytoplasmic sperm injection cycle outcome in POR patients.
Key words: Letrozole, Ovarian reserve, Primary ovarian insufficiency, Ovulation
induction, Fertilization in vitro, Aromatase inhibitors.
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1. Introduction
Poor ovarian response (POR) is a challenging
issue for clinicians, since it was associated
with high cycle cancellation and low pregnancy
rates (1). The ideal controlled ovarian stimulation
(COS) options for patients with POR problem
remain subjective and not evidence-based (2),
and there is still no consensus on the optimal
COS protocol in these patients (3). Accordingly,
different hormonal manipulations were examined
to augment follicular recruitment and to coordinate
subsequent antral follicle growth during COH
in poor responders (4). “A type of hormonal
manipulation included the usage of Letrozole (LZ)
as selective, non-steroidal aromatase inhibitors (AIs)
blocks androgen conversion to estrogen (5, 6).
The LZ-mediated increase ovarian response to
stimulation protocol via enhancing in FSH receptors
affinity and antral follicles growth by reduction
in serum estrogen levels and temporary rise in
intraovarian androgen concentrations which cause
prolongation of the follicular phase (7, 8). In
addition, the decreased serum E2 concentration
associated with LZ may modify the negative impact
of cumulative E2 levels on oocyte quality and
endometrial receptivity in ART cycles(9)” (10). As
an advantage, LZ has no impact on endometrial
thickness and complete endometrial recovery
before implantation and early embryogenesis; since
it has short half-life (approximately 48 hours) and
be completely and rapidly cleaned from systemic
circulation (11).
“Recently, LZ had been recommended in
anovulatory women with high success, and it is
popularly applied in the COS (12). The first studies
regarding adding LZ in COS protocol for POR
patients have reported decreased gonadotropin
consumption (7) and increased number of oocytes
retrieved (8) with this method. After that some
studies compared LZ-adding antagonist protocol
and micro-dose GnRH agonist flare-up protocol in
poor responders and have reported controversial
results (4). Previous studies regarding this field were
different in methodology including the dosage, time
of LZ addition, and the initiation time and dosage
of gonadotropins (13). Yang and colleagues in a
recent study compared the impacts of COH and IVF
outcomes of the following three GnRH antagonist
protocols: (i) use LZ (5 mg) for five days sequentially
overlapping with gonadotropin, (ii) applying LZ (7.5
mg) for three days sequentially with gonadotropin,
and (iii) the standard high-dose gonadotropin
in a GnRH antagonist protocol in poor ovarian
responders (4). They concluded that adding LZ with
antagonist protocol is an affordable and preferable
protocol” (4). In a recent meta-analysis study,
Song and co-workers concluded that the clinical
pregnancy rate may be lower with the antagonist/LZ
protocol than micro-dose GnRH agonist flare-up
protocol for treating poor responders undergoing
IVF/ICSI, but large-scale randomized controlled
trials are required to evaluate the antagonist/LZ
protocol (14).
Consequently, this study was designed as a
double-blind clinical trial to assess the potential
effect of LZ as an adjuvant drug to improve the
outcomes of standard GnRH antagonist stimulation
protocol in patients with POR diagnosis.
2. Materials and Methods
2.1. Patient selection
In this randomized clinical trial which conducted
at the infertility center of Arash Women’s Hospital,
all women with POR diagnosis who underwent in
vitro fertilization/intracytoplasmic sperm injection
and fresh embryo transfer (IVF/ICSI-ET) cycles
were assessed from 3rd February 2017 to 7th
September 2017. POR was defined according to
the Bologna criteria and the patients who had
at least two of the following three criteria were
included: (i) a prior history of POR (retrieved oocytes
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≤3) treatment cycle by the conventional COS, (ii)
advanced maternal age (≥40 yr) or any other
anamnestic risk factors POR (e.g., a history of
ovarian surgery, previous chemotherapy, genetic
abnormalities, shortening of the menstrual cycle),
and (iii) abnormal ovarian reserve test (i.e., antral
follicle count (AFC) < 5–7 follicles or anti-Müllerian
hormone (AMH) < 0.5–1.1 ng/ml). Exclusion
criteria were as follows: premature ovarian failure
diagnosis, donor/recipient treatments, metabolic or
endocrine disorders including hyperprolactinemia
and hypo/hyperthyroidism, endometriosis, body
mass index (BMI) > 30 kg/m2, and azoospermic male
partner.
The previous COS was considered by a minimum
of two or more months to prevent any potential
source of error. Block randomization method with
blocks number six was conducted by statistics
advisor using STATA software version 13 for
randomization of the patients into two groups.
Only the statistics advisor was informed regarding
the random allocation list of patients. In order
to hide the random allocation process, a total
of 160 envelopes of a single drug form were
prepared, a random 10-digit-numbered code was
decided, and a framework was written that was
the relevant drug identification number, with only
the methodologist being aware of the design of
the code. As soon as the patient’s eligibility was
determined by clinical specialists, the statistics
advisor provided the envelope with them and
the grouping type was selected on the basis of
what was inserted in the envelope. All placebo
tablets were produced by Iran hormone company
(Tehran, Iran), which was approved by the Food
and Drug Administration of Iran. The appearance
of the placebo (containing 1 mg folic acid, Iran
hormone, Tehran, Iran) was indistinguishable in
color, shape, size, and smell from LZ tablets. On
the basis of Ebrahimi et al.’s study (14), since folic
acid (1 mg) tablet is administrated preconceptionally
to prevent the fetal nervous system abnormalities
in all infertile patients and it has no effect on
the OS outcome, therefore using additional folic
acid (1 mg) in the control group as placebo is
ethical and logical option. The person evaluating the
outcomes was the third person who was unaware
of the random allocation process and the type of
the treatment. Data analysis was carried out by a
statistician who was unaware of all the processes
of study.
2.2. Treatment protocols
The ovarian stimulation for all study participants
was a flexible regimen of GnRH-antagonist protocol.
The ovarian quiescence was defined by detecting
the serum estradiol (E2) concentrations <60 pg/mL
and absence of ovarian cysts > 10 mm diameter
on vaginal ultrasound scans on day 2 of menstrual
cycle. The baseline serum follicle-stimulating
hormone (FSH), luteinizing hormone (LH), E2, and
progesterone (P) levels were measured on day 2 or
3 of menstrual cycle before starting gonadotropin
stimulation. The eligible patients on 2nd or 3rd
day of menstrual cycle were randomly allocated
into two groups in a 1:1 ratio by either adding
LZ or placebo to GnRH-antagonist stimulation
protocol. In the experimental (LZ) group, the patients
received 5 mg LZ (Letrofem R©; Iran hormone,
Tehran, Iran) on the first five days of OS with
150 IU of recombinant human FSH (Cinnal-f,
Cinagen) and 150 IU of human menopausal
gonadotropin (HMG) (Menogan, Ferring). In the
control group (placebo), the patients received 150 IU
of rFSH and 150 IU of HMG with placebo (containing
1 mg folic acid, Iran hormone, Tehran, Iran). The
follicular growth was evaluated by the serial vaginal
ultrasound (sonographic device: Phillips, affinity
70) and the measurements of serum E2 level.
The dosage of rhFSH was modified individually
on the basis of the ovarian response. The
GnRH antagonist, cetrorelix (Cetrotide R©, Serono
International, Geneva, Switzerland), 0.25 µg/day
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was subcutaneously administrated when follicle(s)
≥13 mm diameter was observed and continued until
the day of triggering of ovulation. The serum P
and E2 levels were measured at the day of human
chorionic gonadotropin (hCG) injection. The final
stage of oocyte maturation was triggered by 10,000
units of hCG (Choriomon, IBSA, InstitutBiochimique
SA), when at least two follicles with ≥18 mm
in diameter was observed and the serum E2
concentration ≥500 pg/mL was measured. The
cycle was cancelled on poor response, if these
criteria were not achieved after 10–12 days of
stimulation. Transvaginal ultrasound-guided oocyte
retrieval was carried out 34–36 hrs. after the
oocyte triggering. The fertilization was done
by conventional ICSI. The obtained embryos at
cleavage stage were replaced under an ultrasound
scan guidance by an embryo transfer catheter
(GuardiaTM, Access ET Catheter, Cook Medical),
two or three days after the oocytes retrieval.
Embryo quality was defined based on the number
and regularity of blastomeres and the degree
of embryonic fragmentation. All patients received
luteal phase support in the form of 400 mg vaginal
progesterone suppository twice daily (Cyclogest,
Actavis, Barnstaple, UK) starting on the oocyte
retrieval evening, and it was continued for 10
weeks in patients with a positive pregnancy test.
A serum β-hCG analysis was performed 14 days
after the ET, and the clinical pregnancy was
detected by observation of gestational sac with
a heartbeat using ultrasound scan 7–10 days
later.
The number of oocytes retrieved and the
number of oocytes MII were considered as primary
outcomes in the present study. The secondary
outcomes were fertilization, implantation, cycle
cancelation, and clinical pregnancy rates, total
gonadotropin dose, duration of OS, the endometrial
thickness and peak serum E2 levels on trigger day,
and a total number of obtained embryos.
2.3. Ethical consideration
The trial protocol was approved by the
Institutional Review Board and the Ethics
Committee of the Tehran University of
Medical Sciences, Tehran, Iran (Ethics code:
IR.TUMS.MEDICINE.REC.1395.1245). The written
informed consent was obtained from the eligible
patients before entering the study.
2.4. Statistical analysis
It was estimated 103 subjects were required
in each study group based on Ebrahimi and
colleagues study (10) and using NCSS-PASS
software (version 2007; NCSS Inc., Kaysville, UT,
USA) with α = 0.05 and 80% power, so a pilot
trial was designed by 80 women in each group
according to the timetable. After the study was
performed, the post-hoc power was calculated
as 70%. The statistical analysis was performed
by Statistical Package for the Social Sciences
(SPSS) (version 20, SPSS Inc., Chicago, Illinois,
USA). The independent t-test and Chi-square test
were used for comparison of qualitative and
quantitative variables between groups respectively.
Descriptive data are reported as mean ± standard
deviation (SD) or number (percent) as appropriate.
Statistical significance level was considered at
p < 0.05.
3. Results
Finally, 206 patients with POR diagnosis were
evaluated and 46 women were excluded due to
the exclusion criteria (n = 35) and not satisfied
to participate (n = 11). No case of dropout was
occurred in both groups; therefore, the data
of 160 participants were analyzed (Figure 1).
Table I compares the demographic and clinical
characteristics of study participants between
groups. There were no significant differences
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between groups in terms of female age, duration of
infertility, BMI, serum AMH, basal FSH, and LH levels,
and AFC before starting the COS protocols. Sixty
women in LZ group (75%) and sixty-four women in
the control (placebo) group (80%) had at least one
history of POR with conventional long-GnRH agonist
protocol.
The outcomes of treatment cycles are reported
in Table II. The dosage of hMG used and the OS
duration and antagonist administration in LZ-treated
group were lower than those of in the placebo
group significantly. There were no differences in the
means of the serum P level on hCG administration
day and the endometrial thickness between groups.
The mean concentration of serum E2 at trigger
day was found to be lower in LZ co-treated group
than that of the control group; however, it was not
statistically significant (p = 0.08). The mean number
of oocytes retrieved, the metaphase II oocytes in
LZ co-treated group were significantly higher than
those of the control group. The fertilization rate, the
mean number of obtained embryos, top quality and
transferred embryos were comparable between
groups. In the control group, the number of patients
with no oocyte result was higher; however, the
difference between the two groups did not reach
the statistical significance level (p = 0.1). There were
no significant differences in implantation and clinical
pregnancy rates between the groups (p = 0.1 and
p = 0.3, respectively).
Table I. The comparison ofdemographic and clinical characteristics of study participants between groups
Variables∗ Letrozole group Control group P-value
Female age (yr)* 37.2 ± 3.3 36.5 ± 3.7 0.2
Female age groups∗∗
≤ 35 yr old 26 (32.5) 30 (37.5)
> 35 yr old 54 (67.5) 50 (62.5)
0.6
Body mass index (kg/m2)∗ 25.9 ± 3.7 26.3 ± 3.4 0.5
Duration of Infertility (yr)∗ 7.3 ± 6.1 6.7 ± 5.1 0.7
No. of couple with primary infertility∗∗ 69 (86.2) 65 (81.2) 0.8
Early follicular phase FSH (IU/L)∗ 8.7 ± 3.6 8.0 ± 2.9 0.1
Early follicular phase LH (IU/L)∗ 6.0 ± 3.5 6.4 ± 5.9 0.6
Early follicular phase E2 (pg/mL)∗ 58.9 ± 6.9 57.3 ± 6.1 0.1
TSH (IU/mL)∗ 2.4 ± 1.4 2.3 ± 1.0 0.6
Prolactin(ng/mL)∗ 17.4 ± 11.0 18.7 ± 8.7 0.4
AMH (ng/mL)∗ 0.65 ± 0.35 0.73 ± 0.31 0.1
Antral follicle count∗ 5.1 ± 2.0 4.8 ± 1.5 0.2
No. of previous failed cycles∗ 1.0 ± 0.9 1.1 ± 0.6 0.5
* Variables were compared between groups and presented as mean ± SD; ** data were compared between groups and presented
as n (%)
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Table II. The comparison of ovarian stimulation and cycle outcomes between the study groups
Variables* Letrozole group Control group P-value
Total rFSH dose (IU)∗ 1433.4 ± 324.4 1490.6 ± 273.0 0.2
Total hMG dose (IU)∗ 1386.5 ± 237.7 1482.1 ± 256.2 0.01
Total gonadotropins dose (IU)∗ 2820 ± 522.4 2972.8 ± 512.1 0.06
Duration of stimulation (Day)* 8.9 ± 1.4 9.7 ± 1.3 0.001
Peak E2 level at trigger (pg/mL)* 776.3 ± 74.9 796.3 ± 72.2 0.08
Serum progesterone at trigger (ng/mL)* 0.87 ± 0.25 0.93 ± 0.26 0.1
Duration of antagonist administration (Day)* 3.5 ± 1.1 4.4 ± 1.4 < 0.001
No. of retrieved oocytes* 3.6 ± 2.5 2.7 ± 1.4 0.008
No. of cases with no oocyte result** 4 (5) 9 (11.1) 0.1
No. of metaphase II oocytes* 3.0 ± 2.2 2.0 ± 1.3 0.002
Fertilization rate (%)* 79.1 ± 32.5 74.1 ± 33.6 0.3
No. of obtained embryos* 1.9 ± 1.4 1.7 ± 1.1 0.4
Top quality embryo n (%)* 1.8 ± 1.1 1.5 ± 1.0 0.1
No. of cases with no embryo result** 12 (15) 11 (13.7) 0.9
No. of embryos transferred* 1.9 ± 1.0 1.8 ± 0.8 0.6
Endometrial thickness at the trigger (mm)* 8.6 ± 1.8 8.8 ± 1.3 0.3
Implantation rate* 15.8 ± 32.2 8.3 ± 19.5 0.1
Clinical pregnancy/ET (%)** 16/64 (25) 11/60 (18.3) 0.3
* Variables were compared between groups and presented as mean ± SD; ** data were compared between groups and presented
as n (%)
p ≤ 0.05 was considered statistically significant
hMG: Human menopause gonadotropin; rFSH: Recombinant follicle-stimulating hormone; No.: Number
Enrollment 
Lost to follow-up (n = 0) 
Follow-Up 
Allocated to intervention (n = 80) 
Received allocated 
Letrozole/Antagonist regimen (n = 80) 
Allocated to intervention (n = 80) 
Received allocated placebo/Antagonist 
regimen (n = 80) 
Allocation 
Assessed for eligibility (n = 206) 
Excluded (n = 46) 
Not meeting inclusion criteria (n = 31) 
Declined to participate (n = 15) 
Analysed (n = 80) 
Analysis 
Lost to follow-up (n = 0) 
Analysed (n = 80) 
Randomized (n = 160) 
Figure 1. Recruitment follow-up and dropouts during the study (Consort flowchart).
4. Discussion
The results of the current trial indicates the
number of oocytes retrieved and that MII oocytes
were improved and a lower dosage of hMG and
antagonist administration and a shorter duration
of stimulation were required with adding LZ. In
addition, the number of cases with no oocyte
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result in the control group was twice. The trend
toward improvement in implantation and clinical
pregnancy rates were observed in the LZ-treated
group; however, it was not statistically significant.
At first, Garcia-Velasco and co-workers assessed
the effect of AIs on ovarian response and
IVF outcomes in patients with POR, using an
OCP/GnRH-antagonist protocol and reported that
LZ-treated patients had significantly higher levels
of follicular fluid testosterone, androstenedione,
and more oocytes retrieved and a higher IR,
despite similar doses of gonadotropins (8). To the
best of the knowledge, there were nine clinical
trials that evaluated the effect of adding LZ to
antagonist protocol (10, 15–22); of these, four trials
compared it with micro-dose GnRH agonist flare-up
protocol (16, 18, 19, 22), three studies with antagonist
protocol without placebo (15, 17, 21), one trial with
placebo/antagonist protocol (10), and one study
with clomiphene/antagonist protocol as control
group (20).
In agreement to the present results, Ozmen
and colleagues evaluated the effect of adding LZ
(5 mg/day) to a fixed dosage (450 IU/day) of r-hFSH
on intra-ovarian androgens and cycle outcomes but
controls with the same r-hFSH dosage alone (15). It
was concluded that adjunctive LZ administration is
beneficial since it reduces both cycle cancellation
rate and cost without an adverse effect on the
outcome (15). Similarly, Bastu and co-workers
compared three different gonadotropin doses with
or without the addition of LZ during the antagonist
protocol in patients with POR. It was found that a
mild stimulation by using LZ was effective as well
as stimulation with higher doses of gonadotropins
alone in these patients (21). Elsewhere, Mohsen
and El Din concluded that adding LZ in antagonist
protocol and micro-dose GnRH agonist flare-up
protocol had same clinical outcomes; however, the
former was more affordable and patient-friendly in
POR (18). However, other studies did not find any
positive effect from adding LZ to conventional GnRH
antagonist protocol and reported some conflicting
results (10, 16, 17, 19, 22). We postulated that the
controversial results between the studies might
be due to the different methodology and using
different criteria and cut-off values for ovarian
reserve tests to define the POR. Moreover, it may
be attributed to the different sample sizes, different
doses of LZ used (2.5 versus 5 mg) and the different
starting days (23). In a double-blind clinical trial with
same inclusion criteria, Ebrahimi and colleagues
found no improvement in clinical outcomes in POR
patients; although the sample size of this study was
low, it can affect the power of the conclusion (10).
4.1. Strengths and limitations of the
study
It should be mentioned that the present study
had some limitations and some strong points. This
study has low power due to difficulties of the
participants enrolment and a low number of the
eligible patients same as previous studies in this
field (5, 7, 8, 10, 15, 24, 25). Although, the main
outcome of the present study were in parallel to
the previous large retrospective and prospective
non-randomized studies (5, 15, 24, 25) in terms
of gonadotropins consumption dosage, E2 level,
and pregnancy rate in the LZ co-treated group, the
present study is one of the clinical trials with large
sample size and proper patient selection based on
“Bologna criteria.” In the present study, patients are
POR and have already had an IVF failure, PGS needs
to be performed for reducing fertility failure as a
result of fetal abnormalities, but these patients were
not willing to apply this approach to their embryos
due to cultural and religious issues.
5. Conclusion
In conclusion, according to the results of the
current clinical trial, adding LZ to the rFSH/hMG
antagonist protocol may improve the outcome of
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the IVF/ICSI cycles in patients with POR. In addition,
considering the evidence provided with previous
studies and current trial, we suggested designing
future studies to evaluate the effect of adjunctive
use of low-dose LZ in conventional OS regimes
on IVF/ICSI outcomes in patients with unexplained
infertility, endometriosis, and PCOS diagnosis.
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